ReviewClinical and experimental medicine2019
Advances in liquid biopsy using circulating tumor cells and circulating cell-free tumor DNA for detection and monitoring of breast cancer.
Review in Clinical and experimental medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Prognostic value of circulating tumor DNA in lymphoma: a meta-analysis.Clinical and experimental medicine · 2022Pooled it
- Advances in diagnosis and treatment of gallbladder cancer: Current status and future directions.World journal of gastrointestinal oncology · 2025Review
- Circulating biomarkers for diagnosis and response to therapies in cancer patients.International review of cell and molecular biology · 2025Review
- Identification of circulating tumor cells captured by the FDA-cleared ParsortixJournal of experimental & clinical cancer research : CR · 2024Article
- Tumor-Agnostic Circulating Tumor DNA Testing for Monitoring Muscle-Invasive Bladder Cancer.International journal of molecular sciences · 2023Article
- Chemically-Modified Sepharose 6B Beads for Collection of Circulating Tumor Cells.Biomolecules · 2023Article
- Circulating tumor DNA sequencing of pediatric solid and brain tumor patients: An institutional feasibility study.Pediatric hematology and oncology · 2023Article
- Article
- Microfluidics for the Isolation and Detection of Circulating Tumor Cells.Advances in experimental medicine and biology · 2022Article
- Resistance to endocrine therapy in HR + and/or HER2 + breast cancer: the most promising predictive biomarkers.Molecular biology reports · 2022Review
- Liquid Biopsy: A Family of Possible Diagnostic Tools.Diagnostics (Basel, Switzerland) · 2021Review
- Targeted Next-Generation Sequencing of Circulating Tumor DNA Mutations among Metastatic Breast Cancer Patients.Current oncology (Toronto, Ont.) · 2021Article
- Review
- Assessment of circulating HISLA as a potential biomarker for breast cancer diagnosis and prognosis.Clinical and experimental medicine · 2021Article
- Case report: 16-yr life history and genomic evolution of an ERCold Spring Harbor molecular case studies · 2020Article
- Liquid Biomarkers for Pediatric Brain Tumors: Biological Features, Advantages and Perspectives.Journal of personalized medicine · 2020Review
- Prospects and challenges of circulating tumor DNA in precision medicine of hepatocellular carcinoma.Clinical and experimental medicine · 2020Review
- Advances in the Detection Technologies and Clinical Applications of Circulating Tumor DNA in Metastatic Breast Cancer.Cancer management and research · 2020Review
- ctcRbase: the gene expression database of circulating tumor cells and microemboli.Database : the journal of biological databases and curation · 2020Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Overview the progress of liquid biopsy using circulating tumor cells (CTCs) and circulating cell-free tumor DNA (cfDNA) to detect and monitor breast cancer. Based on numerous research efforts, the potential value of CTCs and cfDNA in the clinical aspects of cancer has become clear. With the development of next-generation sequencing analysis and newly developed technologies, many technical issues have been resolved, making liquid biopsy widely used in clinical practice. They can be powerful tools for dynamic monitoring of tumor progression and therapeutic efficacy. In the field of breast cancer, liquid biopsy is a research hot spot in recent years, playing a key role in monitoring breast cancer metastasis, predicting disease recurrence and assessing clinical drug resistance. Liquid biopsy has the advantages of noninvasive, high sensitivity, high specificity and real-time dynamic monitoring. Still application is far from reality, but the research and application prospects of CTCs and cfDNA in breast cancer are still worth exploring and discovering. This article reviews the main techniques and applications of CTCs and cfDNA in breast cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.